No Data
INNOVENT BIO (01801): Gary Zieziula has been appointed as a member of the Compensation Committee.
INNOVENT BIO (01801) released an announcement that Chen Kaixian has submitted his resignation as an independent non-executive director to focus on Other career developments...
Innovent Biologics' Lung Cancer Drug Hets NDA Approval From China's NMPA
INNOVENT BIO (01801.HK): The ROS1 inhibitor Dabolat (Dabrafenib capsules) has been approved for marketing by the National Medical Products Administration.
Glory Financial reported on December 20th that INNOVENT BIO (01801.HK) announced the approval from the National Medical Products Administration (NMPA) of China for the new drug application (NDA) of the new generation ROS1 tyrosine kinase inhibitor (TKI) Daborin (Dabrefenib capsules) for the treatment of adult patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed after treatment with ROS1-TKI. Daborin is the company's 13th commercial product, and this innovative precision therapy will benefit lung cancer patients with ROS1 mutations, further strengthening the company's position in tumor precision.
Express News | Innovent Biologics - Nmpa Approved New Drug Application of Dovbleron (Taletrectinib Adipate Capsule)
Bank of America Securities: Reiterates Buy rating for INNOVENT BIO (01801) and HANSOH PHARMA (03692) with both Target Prices raised.
INNOVENT BIO (01801) recently reached a commercialization agreement with Eli Lilly and Co (LLY.US) for its non-covalent (reversible) BTK inhibitor "Jepalibri" in mainland China.
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
No Data
